TY - JOUR
T1 - Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy
T2 - a comparative analysis based on propensity score matching
AU - Kim, Nalee
AU - Kim, Haeyoung
AU - Park, Won
AU - Choi, Doo Ho
AU - Cho, Won Kyung
AU - Nam, Seok Jin
AU - Lee, Jeong Eon
AU - Kim, Seok Won
AU - Yu, Jonghan
AU - Lee, Sei Kyung
AU - Jeon, Byung Joon
AU - Pyon, Jai Kyong
AU - Mun, Goo Hyun
AU - Kim, Tae Gyu
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/2
Y1 - 2022/2
N2 - Purpose: To investigate the impact of immediate breast reconstruction (iBR) on patients treated with post-mastectomy radiation therapy (PMRT) using propensity score matching (PSM). Methods: After a retrospective review of patients treated with PMRT between 2008 and 2017, we included 153 patients who underwent iBR and 872 patients who did not undergo iBR. Among the 153 patients who underwent iBR, 34 received one-stage iBR with autologous tissue and 119 received two-stage iBR. Conventional fractionated PMRT with a total dose of 50–50.4 Gy in 25–28 fractions was performed in all patients. Propensity scores were calculated via logistic regression. Results: Patients who underwent iBR were younger, had early stage disease, and had more frequent hormone receptor-positive tumor than those who did not undergo iBR. After PSM, 127 patients from each group with well-balanced characteristics were selected. With a median follow-up of 67.5 months, iBR led to better 6-year disease-free survival rates compared to no iBR before PSM (84.8% vs. 71.4%, p = 0.003); after PSM, there was no significant difference (84.8% vs. 75.5%, p = 0.130). On multivariable analysis in the matched cohort, iBR was not associated with inferior disease-free survival (hazard ratio, 0.67; p = 0.175). In the sensitivity analysis, iBR was not associated with a lower disease-free survival across all prognostic groups. The 5-year cumulative incidence of iBR failure was 15.0%. Conclusion: In patients with adverse pathologic factors planning to receive PMRT, iBR did not compromise oncologic outcomes. In addition, iBR can be considered in patients treated with PMRT with several clinicopathologic risk factors.
AB - Purpose: To investigate the impact of immediate breast reconstruction (iBR) on patients treated with post-mastectomy radiation therapy (PMRT) using propensity score matching (PSM). Methods: After a retrospective review of patients treated with PMRT between 2008 and 2017, we included 153 patients who underwent iBR and 872 patients who did not undergo iBR. Among the 153 patients who underwent iBR, 34 received one-stage iBR with autologous tissue and 119 received two-stage iBR. Conventional fractionated PMRT with a total dose of 50–50.4 Gy in 25–28 fractions was performed in all patients. Propensity scores were calculated via logistic regression. Results: Patients who underwent iBR were younger, had early stage disease, and had more frequent hormone receptor-positive tumor than those who did not undergo iBR. After PSM, 127 patients from each group with well-balanced characteristics were selected. With a median follow-up of 67.5 months, iBR led to better 6-year disease-free survival rates compared to no iBR before PSM (84.8% vs. 71.4%, p = 0.003); after PSM, there was no significant difference (84.8% vs. 75.5%, p = 0.130). On multivariable analysis in the matched cohort, iBR was not associated with inferior disease-free survival (hazard ratio, 0.67; p = 0.175). In the sensitivity analysis, iBR was not associated with a lower disease-free survival across all prognostic groups. The 5-year cumulative incidence of iBR failure was 15.0%. Conclusion: In patients with adverse pathologic factors planning to receive PMRT, iBR did not compromise oncologic outcomes. In addition, iBR can be considered in patients treated with PMRT with several clinicopathologic risk factors.
KW - Breast cancer
KW - Breast reconstruction
KW - Post-mastectomy radiation therapy
UR - https://www.scopus.com/pages/publications/85123064105
U2 - 10.1007/s10549-021-06483-2
DO - 10.1007/s10549-021-06483-2
M3 - Article
C2 - 35034242
AN - SCOPUS:85123064105
SN - 0167-6806
VL - 192
SP - 101
EP - 112
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -